Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 20/20 | 1.00 |
| ▸ | KIT | P10721 | 4/20 | 0.87 |
| ▸ | FLT3 | P36888 | 4/20 | 0.87 |
| ▸ | CSF1R | P07333 | 3/20 | 0.87 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.79 |
| ▸ | PLK4 | O00444 | 1/20 | 0.79 |
| ▸ | GAK | O14976 | 1/20 | 0.79 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.79 |
| ▸ | STK10 | O94804 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.79 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.79 |
| ▸ | LCK | P06239 | 1/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.79 |
| ▸ | SRC | P12931 | 1/20 | 0.79 |
| ▸ | FLT1 | P17948 | 1/20 | 0.79 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.79 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.79 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.79 |
| ▸ | AXL | P30530 | 1/20 | 0.79 |
| ▸ | FLT4 | P35916 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14009840 | 0.95 | PDGFRB (0.90) | PDGFRBKITFLT3CSF1RPDGFRA | |
| SCHEMBL13330487 | 0.95 | PDGFRB (0.90) | PDGFRBKITFLT3CSF1RPDGFRA | |
| SCHEMBL13524740 | 0.94 | PDGFRB (0.88) | PDGFRBKITFLT3CSF1RPDGFRA | |
| SCHEMBL13524742 | 0.94 | PDGFRB (0.88) | PDGFRBKITFLT3CSF1RPDGFRA | |
| SCHEMBL3891757 | 0.93 | PDGFRB (1.00) | PDGFRBKITFLT3CSF1RPDGFRA | |
| SCHEMBL13773461 | 0.92 | PDGFRB (0.85) | PDGFRBKITFLT3CSF1RPDGFRA | |
| SCHEMBL13330491 | 0.92 | PDGFRB (0.84) | PDGFRBKITFLT3CSF1RPDGFRA | |
| SCHEMBL13330496 | 0.92 | PDGFRB (0.84) | PDGFRBKITFLT3CSF1RPDGFRA | |
| SCHEMBL2921324 | 0.92 | PDGFRB (0.84) | PDGFRBKITFLT3CSF1RPDGFRA | |
| SCHEMBL2922051 | 0.91 | PDGFRB (1.00) | PDGFRBKITFLT3PDGFRAFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882717-B1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-6750218-B2 | INHIBITORY ACTIVITY ON PHOSPHORYLATION OF PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | MILLENNIUMIUM PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | MATSUNO KENJI (JP) | 2003-12-11 | — | — | US | disclosed |
| US-6472391-B2 | INHIBIT PHOSPHORYLATION OF PDGF RECEPTOR TO HINDER ABNORMAL CELL GROWTH AND CELL WANDERING; TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS. | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6207667-B1 | USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6169088-B1 | FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0882717-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | ERBB4, NPR1, PDGFRB | PDGFRB 3/4885KIT 2045/4885FLT3 780/4885 |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | PDGFRB, MKI67, PDGFRA | PDGFRB 1/4885KIT 1535/4885FLT3 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.